Skip to main content Back to Top
Advertisement

7/7/2020

Midazolam Injection

Products Affected - Description

    • Midazolam injection, Akorn, 5 mg/mL, 10 mL vial, 10 count, NDC 17478-0524-10
    • Midazolam injection, Athenex, 1 mg/mL, 2 mL vial, 25 count, NDC 70860-0600-02
    • Midazolam injection, Avet Pharmaceuticals, 5 mg/mL, 5 mL vial, 10 count, NDC 23155-0601-41
    • Midazolam injection, Fresenius Kabi, 1 mg/mL, 5 mL vial, 25 count, NDC 63323-0411-25
    • Midazolam injection, Fresenius Kabi, 5 mg/mL, 1 mL prefilled syringe, 24 count, NDC 76045-0002-10
    • Midazolam injection, Fresenius Kabi, 5 mg/mL, 1 mL fill in 2 mL vial, 25 count, NDC 63323-0412-25
    • Midazolam injection, Fresenius Kabi, 5 mg/mL, 10 mL vial, 10 count, NDC 63323-0412-10
    • Midazolam injection, Hikma, 1 mg/mL, 5 mL vial, 10 count, NDC 00641-6059-10
    • Midazolam injection, Hikma, 5 mg/mL, 1 mL vial, 25 count, NDC 00641-6061-25
    • Midazolam injection, Hikma, 5 mg/mL, 10 mL vial, 10 count, NDC 00641-6060-10
    • Midazolam injection, Hikma, 5 mg/mL, 2 mL vial, 25 count, NDC 00641-6063-25
    • Midazolam injection, Pfizer, 1 mg/mL, 2 mL preservative-free Luer Lock syringe, 10 count, NDC 00409-2306-62
    • Midazolam injection, Pfizer, 1 mg/mL, 2 mL preservative-free iSecure syringe, 10 count, NDC 00409-2306-12
    • Midazolam injection, Pfizer, 5 mg/mL, 1 mL preservative-free Luer Lock syringe, 10 count, NDC 00409-2307-60
    • Midazolam injection, Pfizer, 5 mg/mL, 1 mL preservative-free vial, 10 count, NDC 00409-2308-01
    • Midazolam injection, Pfizer, 5 mg/mL, 10 mL vial, 10 count, NDC 00409-2596-05
    • Midazolam injection, Pfizer, 5 mg/mL, 2 mL preservative-free vial, 10 count, NDC 00409-2308-02
    • Midazolam injection, Pfizer, 5 mg/mL, 5 mL vial, 10 count, NDC 00409-2596-03

Reason for the Shortage

    • Akorn has midazolam injection on shortage due to increased demand.
    • Athenex has midazolam injection on shortage due to increased demand.
    • Avet has midazolam injection on shortage due to increased demand.
    • Fresenius Kabi has midazolam injection on shortage due to increased demand. They are not marketing the 5 mg/mL 5 mL vials and 5 mg/mL 2 mL syringes.
    • Hikma did not provide a reason for the shortage.
    • Pfizer has midazolam injection on shortage due to manufacturing delays and increased demand.

Available Products

    • Midazolam injection, Athenex, 5 mg/mL, 10 mL vial, 10 count, NDC 70860-0601-10
    • Midazolam injection, Avet Pharmaceuticals, 1 mg/mL, 2 mL vial, 25 count, NDC 23155-0600-41
    • Midazolam injection, Avet Pharmaceuticals, 5 mg/mL, 10 mL vial, 10 count, NDC 23155-0601-42
    • Midazolam injection, Fresenius Kabi, 1 mg/mL, 10 mL vial, 10 count, NDC 63323-0411-10
    • Midazolam injection, Fresenius Kabi, 1 mg/mL, 2 mL prefilled syringe, 24 count, NDC 76045-0001-20
    • Midazolam injection, Fresenius Kabi, 1 mg/mL, 2 mL vial, 25 count, NDC 63323-0411-12
    • Midazolam injection, Fresenius Kabi, 5 mg/mL, 2 mL vial, 25 count, NDC 63323-0412-02
    • Midazolam injection, Hikma, 1 mg/mL, 10 mL vial, 10 count, NDC 00641-6056-10
    • Midazolam injection, Hikma, 1 mg/mL, 2 mL vial, 25 count, NDC 00641-6057-25
    • Midazolam injection, Pfizer, 1 mg/mL, 10 mL vial, 10 count, NDC 00409-2587-05
    • Midazolam injection, Pfizer, 1 mg/mL, 2 mL preservative-free vial, 25 count, NDC 00409-2305-17
    • Midazolam injection, Pfizer, 1 mg/mL, 5 mL preservative-free vial, 10 count, NDC 00409-2305-05

Estimated Resupply Dates

    • Akorn has 5 mg/mL 10 mL vials on allocation.
    • Athenex has midazolam 1 mg/mL 2 mL vials on back order and the company cannot estimate a release date.
    • Avet has midazolam 5 mg/mL 5 mL vials on back order and the company estimates a release date of August 2020.
    • Fresenius Kabi has midazolam 5 mg/mL 10 mL vials on back order and the company estimates a release date of late-July 2020. The 5 mg/mL 1 mL vials are on back order and the company estimates a release date of mid-July 2020. The 5 mg/mL 1 mL syringes are on back order and the company cannot estimate a release date. The 1 mg/mL 1 mL vials are on back order and the company estimates a release date of mid-July 2020. Check wholesalers for inventory.
    • Hikma has midazolam 1 mg/mL 5 mL vials on back order and the company estimates a release date of early-August 2020. The 5 mg/mL 1 mL and 2 mL vials are on back order and the company estimates a release date of early-August 2020 for the 1 mL vials and early-July 2020 for the 5 mL vials. The 5 mg/mL 10 mL vials are on back order and the company cannot estimate a release date.
    • Pfizer has midazolam 1 mg/mL 2 mL Carpuject syringes and 5 mg/mL 1 mL Carpuject syringes on back order and the company estimates a release date of June 2021. The 1 mg/mL 2 mL iSecure syringes are on back order and the company estimates a release date of February 2023. The 5 mg/mL 1 mL preservative-free vials are on back order and the company estimates a release date of July 2020. The 5 mg/mL 2 mL preservative-free vials are available in limited supply. The 5 mg/mL 5 mL vials are on back order and the company estimates a release date of July 2020. The 5 mg/mL 10 mL vials are available in limited supply.

Updated

Updated July 7, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 25, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.